Loss of VGLL4 suppresses tumor PD‐L1 expression and immune evasion

Targeting immune checkpoints, such as PD‐L1 and its receptor PD‐1, has opened a new avenue for treating cancers. Understanding the regulatory mechanism of PD‐L1 and PD‐1 will improve the clinical response rate and efficacy of PD‐1/PD‐L1 blockade in cancer patients and the development of combinatoria...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EMBO J
Egile Nagusiak: Wu, Ailing, Wu, Qingzhe, Deng, Yujie, Liu, Yuning, Lu, Jinqiu, Liu, Liansheng, Li, Xiaoling, Liao, Cheng, Zhao, Bin, Song, Hai
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6589543/
https://ncbi.nlm.nih.gov/pubmed/30396996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.201899506
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak